1. Home
  2. BETR vs BWAY Comparison

BETR vs BWAY Comparison

Compare BETR & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

HOLD

Current Price

$29.09

Market Cap

492.2M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$13.65

Market Cap

450.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BETR
BWAY
Founded
2014
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
492.2M
450.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BETR
BWAY
Price
$29.09
$13.65
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$40.00
$13.25
AVG Volume (30 Days)
351.7K
130.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$51.61
$301.23
Revenue Next Year
$62.67
$24.33
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$9.50
$7.84
52 Week High
$94.06
$26.63

Technical Indicators

Market Signals
Indicator
BETR
BWAY
Relative Strength Index (RSI) 42.96 29.39
Support Level $25.33 $11.55
Resistance Level $35.07 $17.20
Average True Range (ATR) 3.85 1.05
MACD 0.07 -0.64
Stochastic Oscillator 2.32 14.18

Price Performance

Historical Comparison
BETR
BWAY

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: